TM
MAZE

Torren Management’s Maze Therapeutics MAZE Stock Holding History

Torren Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34K Hold
112
– – ﹤0.01% 435
2026
Q1 		$3.34K Hold
112
– – ﹤0.01% 412
2025
Q4 		$4.64K Buy
+112
New +$3.85K ﹤0.01% 913

Other funds holding MAZE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MGB
Mass General Brigham Somerville, Massachusetts $361M AUM
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Torren Management's MAZE Position: Q2 2026 in Review

Torren Management held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 112 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #435.

Torren Management first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.64K in Q4 2025. 39 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Torren Management held 112 shares of Maze Therapeutics worth $3.34K as of Q2 2026.
  • Torren Management left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #435 holding.
  • Torren Management first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Maze Therapeutics position peaked at $4.64K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.